# GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

> **NCT07301268** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 36 (estimated)

## Conditions studied

- Glioblastoma, IDH-Wildtype
- Progressive Astrocytoma, IDH-Mutant, Grade 4
- Progressive Glioblastoma
- Progressive Gliosarcoma
- Recurrent Astrocytoma, IDH-Mutant, Grade 4
- Recurrent Glioblastoma, IDH-Wildtype
- Recurrent Gliosarcoma
- Resectable Astrocytoma
- Resectable Glioblastoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography Test
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Multigated Acquisition Scan
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Surgical Procedure

## Key facts

- **NCT ID:** NCT07301268
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2029-04-30
- **Final completion:** 2034-04-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07301268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07301268, "GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07301268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*